When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
A weekend leverage flush pushed BTC below $88,000 before a sharp rebound. Bitcoin is trading at a pivotal level that analysts say could determine whether the market holds its broader uptrend or slips ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...
Recursion Pharmaceuticals stock jumped 16% on October 8, 2025, reaching around $6.08 after falling 5.4% the previous day on broader market weakness. The company reported Q2 2025 revenue of $19.2 ...
Recursion Pharmaceuticals (RXRX) closed at $4.77 in the latest trading session, marking a -1.24% move from the prior day. This change lagged the S&P 500's 0.47% gain on the day. Meanwhile, the Dow ...
A variation of a puzzle called the “pick-up sticks problem” asks the following question: If I have some number of sticks with random lengths between 0 and 1, what are the chances that no three of ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results